1350454-70-4

Basic information

• Product Name: [3H]BMS-725519
• CAS NO: 1350454-70-4
• Molecular Weight: 486.836
• Mol File: 1350454-70-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [3H]BMS-725519(CAS DataBase Reference)
• NIST Chemistry Reference: [3H]BMS-725519(1350454-70-4)
• EPA Substance Registry System: [3H]BMS-725519(1350454-70-4)

Safety Data

• Hazardous Substances Data: 1350454-70-4(Hazardous Substances Data)

Upstream product

• 1350438-47-9 C₁₅H₈Cl₂IN₃ 
• 1350438-48-0 C₁₆H₉ClIN₅O 
• 917969-77-8 2-chloro-3-(chloromethyl)-6-(trifluoromethyl)pyridine 
• 1350438-49-1 C₂₃H₁₂Cl₂F₃IN₆O 
• 1350438-50-4 C₂₃H₁₂ClF₃I₂N₆O 
• 917396-39-5 [2-chloro-6-(trifluoromethyl)pyridin-3-yl]methanol 
• 1350438-42-4 C₈H₄ClIN₂O 
• 1350438-43-5 C₈H₅BrClIO 
• 1350438-51-5 C₈H₁₁N₃O₃S 
• 1350438-44-6 C₁₆H₁₅ClIN₃O₄S 
• 1350438-45-7 C₁₅H₁₁ClIN₃O₂ 
• 1350438-46-8 C₁₅H₉ClIN₃O 
• 42860-04-8 4-chloro-3-iodobenzoic acid 
• 6622-91-9 2-(pyridine-4-yl)acetic acid hydrochloride 

Relevant articles and documents

Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies

Obesity remains a significant public health issue leading to Type II diabetes and cardiovascular disease. CB1 antagonists have been shown to suppress appetite and reduce body weight in animal models as well as in humans. Evaluation of pre-clinical CB1 antagonists to establish relationships between in vitro affinity and in vivo efficacy parameters are enhanced by ex vivo receptor occupancy data. Synthesis and biological evaluation of a novel and highly selective radiolabeled CB1 antagonist is described. The radioligand was used to conduct ex vivo receptor occupancy studies.